IRWD - Ironwood Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
12.72
-0.19 (-1.47%)
At close: 4:00PM EST

12.72 0.00 (0.00%)
After hours: 4:31PM EST

Stock chart is not supported by your current browser
Previous Close12.91
Open12.80
Bid9.45 x 800
Ask14.60 x 1800
Day's Range12.19 - 12.83
52 Week Range9.07 - 21.20
Volume1,360,610
Avg. Volume1,574,890
Market Cap1.96B
Beta (3Y Monthly)2.45
PE Ratio (TTM)N/A
EPS (TTM)-1.68
Earnings DateFeb 12, 2019 - Feb 18, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.71
Trade prices are not sourced from all markets
  • Markit5 days ago

    See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.

    # Ironwood Pharmaceuticals Inc ### NASDAQ/NGS:IRWD View full report here! ## Summary * Bearish sentiment is moderate and increasing ## Bearish sentiment Short interest | Negative Short interest is moderately high for IRWD with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on January 10. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $2.05 billion over the last one-month into ETFs that hold IRWD are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • How to spot risky biotech companies and six to avoid now
    MarketWatch6 days ago

    How to spot risky biotech companies and six to avoid now

    With biotechnology exchange traded funds down as much as 20% from their highs last year, it’s now tempting to shop for bargains. It had cash of $11 million and annualized losses of $94 million, for a very troubling risk ratio of 0.1.

  • Ironwood's (IRWD) Linzess Gets Approval in China for IBS-C
    Zacks6 days ago

    Ironwood's (IRWD) Linzess Gets Approval in China for IBS-C

    Ironwood Pharmaceuticals (IRWD) gets approval for Linzess in China for the treatment of adults with IBS-C

  • Business Wire7 days ago

    Ironwood Pharmaceuticals Announces Approval of LINZESS® (linaclotide) in China for the Treatment of Adults with IBS-C

    Ironwood Pharmaceuticals, Inc. (IRWD), a commercial biotechnology company, today announced that the National Medical Products Administration (NMPA) approved the marketing application for LINZESS® (linaclotide) for adults with irritable bowel syndrome with constipation (IBS-C) in China. Ironwood anticipates that it will launch the drug with its partner in China, AstraZeneca, in the second half of 2019.

  • Markit8 days ago

    See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.

    # Ironwood Pharmaceuticals Inc ### NASDAQ/NGS:IRWD View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and increasing ## Bearish sentiment Short interest | Negative Short interest is moderately high for IRWD with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on January 10. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, growth of ETFs holding IRWD is favorable, with net inflows of $4.93 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Ironwood to Get New CEO, Current CEO to Head Latest Spinoff
    Zacks15 days ago

    Ironwood to Get New CEO, Current CEO to Head Latest Spinoff

    Ironwood Pharma (IRWD) appoints AstraZeneca executive, Mark Mellon, as its new chief executive officer. Peter Hecht, the current CEO, will lead the new spinoff company focusing on rare disease.

  • Business Wire16 days ago

    Ironwood Pharmaceuticals Appoints Michael Shetzline, M.D., Ph.D. as Chief Medical Officer

    Ironwood Pharmaceuticals, Inc. (IRWD) today announced that Michael Shetzline, M.D., Ph.D., will join Ironwood as chief medical officer, senior vice president and head of drug development, effective January 28, 2019. Dr. Shetzline will lead global product development for Ironwood following its planned separation into two independent, publicly-traded companies.

  • The Wall Street Journal18 days ago

    Ironwood Pharmaceuticals Picks AstraZeneca Executive to Be Next CEO

    An executive at British drugmaker AstraZeneca PLC has been tapped to lead Ironwood Pharmaceuticals Inc. after the biotech company reorganizes to focus on selling drugs for stomach diseases. Mark Mallon is slated to join Ironwood, the company said, after a 24-year career at AstraZeneca, most recently overseeing strategy. Mr. Mallon will initially serve as an adviser to the Ironwood board and then take over from Ironwood CEO Peter Hecht after the company spins out a new firm developing drugs for rare diseases, Ironwood said.

  • Ironwood co-founder, CEO will step down to head new spinout
    American City Business Journals18 days ago

    Ironwood co-founder, CEO will step down to head new spinout

    Mark Mallon will replace co-founder and current CEO Peter Hecht, who will move to the new rare disease-focused biotech spinoff.

  • Ironwood Pharmaceuticals Announces Chief Executive Officers to Lead Ironwood and Cyclerion, Effective Upon Upcoming Separation
    Business Wire18 days ago

    Ironwood Pharmaceuticals Announces Chief Executive Officers to Lead Ironwood and Cyclerion, Effective Upon Upcoming Separation

    Ironwood Pharmaceuticals, Inc. (IRWD) today announced that the Ironwood board of directors has appointed chief executive officers (CEOs) of the two companies, effective at the time of Ironwood’s planned separation which is on track to be completed in the first half of 2019. Industry veteran Mark Mallon will become CEO and a director of Ironwood, a gastrointestinal (GI) healthcare company. Mr. Mallon is joining Ironwood effective immediately as executive senior advisor, working closely with Peter Hecht, founding CEO of Ironwood, through the separation.

  • Ironwood/Allergan Settle Linzess Patent Litigation With Mylan
    Zacks19 days ago

    Ironwood/Allergan Settle Linzess Patent Litigation With Mylan

    Ironwood (IRWD) and Allergan announce agreement with Mylan to resolve patent litigation, granting Mylan license to launch a generic version of Linzess in the United States not earlier than Feb 5, 2030.

  • Business Wire20 days ago

    Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

    Ironwood Pharmaceuticals, Inc. (IRWD) will present a corporate update at the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2018 at 10:00 a.m. Pacific Time / 1:00 p.m. Eastern Time at the Westin St. Francis Hotel in San Francisco. The presentation will be followed by a question and answer session that will begin at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time. A live webcast of Ironwood’s presentation and the question and answer session will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com.

  • Business Wire20 days ago

    Ironwood and Allergan Announce Settlement with Mylan Resolving LINZESS® (linaclotide) Patent Litigation

    Ironwood Pharmaceuticals, Inc. (IRWD) and Allergan plc (AGN) announced today that the companies have reached an agreement with Mylan Pharmaceuticals, Inc. (MYL) resolving patent litigations brought in response to Mylan’s abbreviated new drug applications (ANDAs) seeking approval to market generic versions of LINZESS (linaclotide) prior to the expiration of the companies’ applicable patents. The settlement with Mylan is the third patent infringement settlement the companies have reached with respect to LINZESS.

  • See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.
    Markit27 days ago

    See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.

    Short interest is moderate for IRWD with between 5 and 10% of shares outstanding currently on loan. Over the last month, growth of ETFs holding IRWD is favorable, with net inflows of $4.29 billion. According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising.

  • Hedge Funds Are Betting On Ironwood Pharmaceuticals, Inc. (IRWD)
    Insider Monkeylast month

    Hedge Funds Are Betting On Ironwood Pharmaceuticals, Inc. (IRWD)

    Hedge fund managers like David Einhorn, Dan Loeb, or Carl Icahn became billionaires through reaping large profits for their investors, which is why piggybacking their stock picks may provide us with significant returns as well. Many hedge funds, like Paul Singer’s Elliott Management, are pretty secretive, but we can still get some insights by analyzing […]

  • Thomson Reuters StreetEventslast month

    Edited Transcript of IRWD earnings conference call or presentation 6-Nov-18 1:30pm GMT

    Q3 2018 Ironwood Pharmaceuticals Inc Earnings Call

  • Simply Wall St.last month

    Is Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Overpaying Its CEO?

    Peter Hecht became the CEO of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) in 1998. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then we'll Read More...

  • Why Is Ironwood (IRWD) Up 6.7% Since Last Earnings Report?
    Zacks2 months ago

    Why Is Ironwood (IRWD) Up 6.7% Since Last Earnings Report?

    Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.

    Short interest is moderately high for IRWD with between 10 and 15% of shares outstanding currently on loan. The net inflows of $637 million over the last one-month into ETFs that hold IRWD are not among the highest of the last year and have been slowing.

  • See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.

    Short interest is moderately high for IRWD with between 10 and 15% of shares outstanding currently on loan. Over the last one-month, outflows of investor capital in ETFs holding IRWD totaled $740 million.

  • See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.

    Short interest is moderate for IRWD with between 5 and 10% of shares outstanding currently on loan. The net inflows of $622 million over the last one-month into ETFs that hold IRWD are among the lowest of the last year and appear to be slowing.

  • See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.

    Ironwood Pharmaceuticals Inc NASDAQ/NGS:IRWD

  • Most Analysts Are Bullish on Nektar Stock
    Market Realist2 months ago

    Most Analysts Are Bullish on Nektar Stock

    In November 2018, of the total ten analysts covering Nektar Therapeutics (NKTR), eight analysts have given the stock a “buy” or higher rating, and two analysts have given it a “hold” rating. The mean rating for Nektar Therapeutics stock is 1.8 with a target price of $88.5, implying an upside potential of 160.1% over Nektar Therapeutics’ trading price of $34.03 on November 10.

  • Analyzing Nektar Therapeutics’ Q3 Operational Performance
    Market Realist2 months ago

    Analyzing Nektar Therapeutics’ Q3 Operational Performance

    Nektar Therapeutics (NKTR) incurred general and administrative expenses of $18.72 million in the third quarter of 2018 as compared with $12.06 million in the third quarter of 2017. Nektar Therapeutics expects general and administrative expenses in fiscal 2018 to be higher than they were in fiscal 2017.

  • How Nektar Therapeutics’ Gross Margin Trended
    Market Realist2 months ago

    How Nektar Therapeutics’ Gross Margin Trended

    Nektar Therapeutics’ (NKTR) non-cash royalty revenue associated with the sale of future royalties increased from $8.07 million in the third quarter of 2017 to $8.37 million in the third quarter of 2018. The significant drop in Nektar’s total revenues was attributable to a decline in license, collaboration, and other revenues, which decreased from $131.11 million in the third quarter of 2017 to $4.87 million in the third quarter of 2018.